The Climate for Investing in Platform Technologies
This article was originally published in Start Up
The founder and CEO of Flagship Ventures, Noubar Afeyan, points to several reasons why early-stage investing should be on the upswing.
You may also be interested in...
In Brief February 2007
A short summary of recent clinical and market developments in the medical device industry.
Synthetic Biology: Amplifying Throughput in Discovery at Marginal Cost
An example of the looming power of synthetic biology, one of its first start-ups, Codon Devices, is providing researchers with hundreds of specified protein variants using automated, microarray-based fabrication methods. Its platform could help address pharma's productivity problem by decreasing the size of a discovery pipeline and shrinking the development timeline, and position the company to negotiate downstream payments for its efforts based on the success of clients' development programs.
Harbingers For IPF Drug Development
Roche’s decision to discontinue a Phase III program in idiopathic pulmonary fibrosis was the latest of several recent late-stage clinical failures, emblematic of the difficulty in finding new approaches to treat the disease.